Кселода Drug photo

The description is actual on 16.03.2015

  • Latin name: Xeloda
  • ATH code: L01BC06
  • Active ingredient: Kapetsitabin (Capecitabine)
  • Producer: F.Khoffmann-Lya Ltd. Groves, Switzerland


Active component kapetsitabin is a part of tablets.

Additional components: lactose, gipromelloza, sodium of a kroskarmelloz, gipromelloz, magnesium stearate, MKTs.

The cover consists from: Opadray peach of Ys-1-17255-A, talc, titanium of dioxide, ferrous oxide yellow and red.

Release form

Kseloda in the form of tablets, coated, packaged in blisters on 10 pieces is issued. Tablets of 150 mg are placed in packs on 6 blisters, medicine of 500 mg – on 12 blisters. Besides, packaging in bottles, on 60 and 120 tablets, respectively is possible.

Pharmacological action

Antineoplastic action is characteristic of Kseloda.

Pharmacodynamics and pharmacokinetics

The main substance of drug – kapetsitabin, is derivative a ftorpirimidina of a carbamate and the peroral tsitostatik capable to be activated in a tumor, showing considerable selection cytotoxic effect. At the same time cytotoxic action is characteristic to metabolites of this substance.

Thanks to consecutive fermental biotransformation of a kapetsitabin in 5-FU, the increased concentration of substance which are found in a tumor, but not in the healthy fabrics surrounding it are created. As a result of the difficult mechanism of action, drug exerts impact on harmful cells, suppressing their further development.

In an organism kapetsitabin is exposed to fast and full absorption. Then it is transformed to metabolites: 5 -dezoksi-5-ftoruridin (5 -DFUR) and 5 -dezoksi-5-ftortsitidin (5 -DFTsT). The use of food can reduce absorbability of a kapetsitabin, but does not exert special impact on metabolites. The maximum concentration comes to light 1,5-3,5 hours later.

The metabolism of drug occurs mainly in a liver then metabolites which exert impact on affected areas are formed.

Removal from an organism is carried out in the form of metabolites as a part of urine, a calla and small part in an invariable form.

Indications to use

As a rule, Kseloda is appointed:

  • in a combination therapy with dotsetaksely a metastatic or locally-spread breast cancer if the chemotherapy is inefficient, including drug from an anthracycline number of taxons, and also at contraindications to treatment by anthracyclines;
  • for adjuvant therapy of a colon cancer;
  • in therapy of the first line of a metastatic colorectal cancer, and also a widespread carcinoma of the stomach.

Contraindications to use

It is necessary to refrain from reception of this drug at:

  • hypersensitivity to a kapetsitabin and other derivatives of a ftorpirimidin, other components of drug;
  • the established deficit a dehydrogenase dihydropyrimidine;
  • concomitant use of a sorivudin, and also its structural analogs;
  • heavy renal failure;
  • lactations, pregnancies;
  • age it is less than 18 years;
  • incompatibility with other components of a combination therapy.

Respect for care is required at:

  • age of patients of 60 flyings;
  • simultaneous treatment by peroral anticoagulants.

Side effects of Kseloda

At treatment by Kseloda the side effects differing in big variety can develop. Usually they are marked out in a look: diarrheas, stomatitis, nausea, vomiting, palmar and bottom syndrome, strong fatigue, weakness, block, drowsiness.

Development of the disturbances connected with activity of system of digestion, a condition of integuments and appendages, nervous, respiratory, musculoskeletal, cardiovascular and other systems is possible.

Deviations in work of sense bodys, systems of a hemopoiesis, development of infectious complications, change of laboratory indicators are not excluded.

It is possible to carry to other side effects: fever, dehydration, lowering of body weight, block, pain in spin.

Application instruction of Kseloda (Way and dosage)

The application instruction of Kseloda specifies that drug is intended for intake, it is desirable within half an hour after the use of food, washing down with water.

At monotherapy of a colorectal cancer, colon cancer and a mammary gland the standard daily dosage of drug makes 1250 mg to the 2nd one-time reception – in the morning and in the evening. Treatment is carried out for 3 weeks, then do a break for 7 days.

Purpose of drug in a combination therapy demands special approach, strict accounting of compatibility of medicines, features of a course of a disease and the patient's organism.


In case of overdose the symptoms shown in the form of diarrhea, nausea, vomiting, an inflammation of a mucous membrane, bleedings or irritation of a gastrointestinal tract, oppression of activity of marrow can develop.

At the same time treatment includes the therapeutic and supporting procedures allowing to eliminate clinical symptoms and to prevent development of complications.


Kseloda's appointment in combination with anticoagulants of a coumarinic row, for example: Warfarin and Fenprokumon, can exert a negative impact on a blood coagulation, causing bleedings.

It is recommended to be careful at simultaneous treatment with P450 cytochrome substrates.

The combination to Phenytoinum can increase its concentration as a part of a blood plasma. Therefore regular control of indicators of blood is required.

Folinat of considerable impact on pharmacokinetics of a kapetsitabin or metabolites does not render calcium, but strengthening of toxic effect as its influence on their pharmacodynamics is possible is not excluded.

Combinations with Sorivudin or his analogs cause clinically significant interaction with metabolites, capable to cause fatal strengthening of toxicity of ftorpirimidin. For this reason between receptions of these drugs it is necessary to take a break not less than 4 weeks.

Terms of sale

In Kselodu's drugstores it is possible to get only according to the recipe of the specialist.

Storage conditions

Storage of this drug requires the cool place unavailable to children.

Period of validity

3 years.

Kseloda's analogs

Coincidence on the ATH code of the 4th level:

The main analogs are provided by drugs: Kapetsitabin, Kapetsitover, Tutabin.

Kseloda or Tutabin — what is better?

It is known that Kseloda and Tutabin are created on the basis of one active ingredient – a kapetsitabin. Therefore, according to specialists, there is no special difference in efficiency of drugs.

However relatives of the patients having cancer diseases report that Kseloda appears more effective in comparison with Tutabin. At the same time it should be noted that Tutabin write out in policlinic for receiving according to the free recipe while Kselodu should buy, and in drugstores it meets not always.

Of course, on the Internet many such messages meet: I will give or will sell Kseloda 500 mg. But to make similar purchases risky as nobody will be able to guarantee quality of drug.


During treatment to take alcohol categorically contraindicated.


  • Kseloda of 150 mg No. 60 tabletkihoffman La Roche
  • Kseloda of 500 mg No. 120 tabletkihoffman La Roche

Drugstore of IFC

  • Kseloda tbl p / about 150 mg No. 60, F.Khoffmannlyaroshltd / Hoffmann la Rosh of INKSSH
to show still


  • Kselodahoffmann-La Roche (USA)
  • Kselodahoffmann-La Roche (USA)
Section: Antineoplastic
PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before use of medicine of Kselod surely consult with the attending physician.